Intraperitoneal chemotherapy for frontline ovarian cancer therapy: Vindicated or vilified?

被引：0
作者：
Robert L. Coleman
机构：
来源：
Current Oncology Reports | 2006年 / 8卷 / 6期
关键词：
Overall Survival; Ovarian Cancer; Paclitaxel; Intraperitoneal Chemotherapy; Gynecologic Oncology Group;
D O I：
10.1007/s11912-006-0072-y
中图分类号：
学科分类号：
摘要：
A regimen of IV paclitaxel plus IP cisplatin and paclitaxel improves both PFS and OS in patients with optimally cytoreduced stage III ovarian cancer relative to IV cisplatin and paclitaxel.
引用
收藏
页码：439 / 440
页数：1
相关论文
共 9 条
  • [1] Alberts DS(1996)Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N Engl J Med 335 1950-1955
  • [2] Liu PY(2001)Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J Clin Oncol 19 1001-1007
  • [3] Hannigan EV(2006)Intraperitoneal catheter outcomes on GOG 172: randomized trial of IV vs. IP chemotherapy in optimal ovarian cancer Gynecol Oncol 100 27-32
  • [4] Markman M(undefined)undefined undefined undefined undefined-undefined
  • [5] Bundy BN(undefined)undefined undefined undefined undefined-undefined
  • [6] Alberts DS(undefined)undefined undefined undefined undefined-undefined
  • [7] Walker JL(undefined)undefined undefined undefined undefined-undefined
  • [8] Armstrong D(undefined)undefined undefined undefined undefined-undefined
  • [9] Bundy B(undefined)undefined undefined undefined undefined-undefined
1